Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211

2009337 citationsJournal Article

Authors

Motoko Yamaguchi · Japanese Foundation For Cancer Research

Kensei Tobinai · Japanese Foundation For Cancer Research

Masahiko Oguchi · Japanese Foundation For Cancer Research

Naoki Ishizuka · Japanese Foundation For Cancer Research

Yukio Kobayashi · Japanese Foundation For Cancer Research

Yasushi Isobe · Japanese Foundation For Cancer Research

Kenichi Ishizawa

Abstract

Concurrent chemoradiotherapy using multidrug resistance-nonrelated agents and etoposide is a safe and effective treatment for localized nasal NK/T-cell lymphoma and warrants further investigation.

Topics & Keywords

Lymphoma Diagnosis and Treatment Viral-associated cancers and disorders Immune Cell Function and Interaction

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 27, Issue 33, pp. 5594-5600

DOI: 10.1200/jco.2009.23.8295

Field-Weighted Citation Impact: 14.36